Your browser version may not work well with NCBI's Web applications. More information here...
1: J Neurol Sci. 2008 Jul 4. [Epub ahead of print]Click here to read Links

Blocking alpha4-integrins - A small molecule approach to treatment of multiple sclerosis.

Davenport RJ, Munday JR.

UCB, Granta Park, Great Abington, Cambridge, CB21 6GS, UK.

Inhibition of leukocyte trafficking using antibody blockade of the alpha4 (alpha4)-integrins has now been validated as a therapeutic approach for the treatment of multiple sclerosis (MS). This positive validation has led to the discovery of small molecule alpha4 antagonists that are progressing through clinical trials. The challenges in development of these antagonists will be discussed along with a clinical update on the most advanced candidates.

PMID: 18603264 [PubMed - as supplied by publisher]

Related Articles